Visceral and Cutaneous Leishmaniasis Recommendations for Solid Organ Transplant Recipients and Donors

Transplantation. 2018 Feb;102(2S Suppl 2):S8-S15. doi: 10.1097/TP.0000000000002018.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiprotozoal Agents / adverse effects
  • Antiprotozoal Agents / therapeutic use*
  • Donor Selection / methods*
  • Donor Selection / standards
  • Host-Parasite Interactions
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / adverse effects
  • Latin America
  • Leishmania donovani / drug effects*
  • Leishmania donovani / isolation & purification
  • Leishmania donovani / pathogenicity
  • Leishmaniasis, Cutaneous / diagnosis
  • Leishmaniasis, Cutaneous / drug therapy*
  • Leishmaniasis, Cutaneous / parasitology
  • Leishmaniasis, Cutaneous / transmission
  • Leishmaniasis, Visceral / diagnosis
  • Leishmaniasis, Visceral / drug therapy*
  • Leishmaniasis, Visceral / parasitology
  • Leishmaniasis, Visceral / transmission
  • Organ Transplantation / adverse effects
  • Organ Transplantation / methods*
  • Organ Transplantation / standards
  • Practice Guidelines as Topic
  • Risk Assessment
  • Risk Factors
  • Tissue Donors*
  • Transplant Recipients*
  • Treatment Outcome

Substances

  • Antiprotozoal Agents
  • Immunosuppressive Agents